RecruitingPhase 3NCT06847724

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Studying Opsoclonus-myoclonus syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sandoz
Intervention
CYB704(biological)
Enrollment
175 target
Eligibility
18-55 years · All sexes
Timeline
20252029

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06847724 on ClinicalTrials.gov

Other trials for Opsoclonus-myoclonus syndrome

Additional recruiting or active studies for the same condition.

See all trials for Opsoclonus-myoclonus syndrome

← Back to all trials